Skip to main content

CM Life Sciences II Inc. (CMII)

NASDAQ Stock Market Financial Services Shell CompaniesView data quality →
25.1Poor

ValueMarkers Composite Index

Top 0%#44,714 of 44,714

DCF data not available

Piotroski
0/9
Weak
Beneish
-
Altman
-
DCF Value
-
N/A
ROIC
-
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

CM Life Sciences II Inc. (CMII) — VMCI valuation read

CM Life Sciences II Inc. (CMII) carries a VMCI composite of 25/100, 25 points below the Financial Services sector median of 50. Among mid-cap names, that gap places CMII in the bottom third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).

The CMII insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.

**Investor frame.** Value reads CMII trades at 26.0x earnings, 44% above the Financial Services median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Financial Services 12.0x. Quality: ROIC of 14.0% sits 4.0pp above the Financial Services median (10.0%). Risk: net debt to EBITDA of -0.8x leaves covenant headroom, the line to track on CM Life Sciences II Inc.'s next 10-Q.

CMII fell 0.6% over the trailing 7 days, with a +0.9% read on a 30-day basis.

CM Life Sciences II Inc. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the life sciences sector. The company was incorporated in 2020 and is based in New York, New York.

CEO: Eli Decatur CasdinUSii.cmlifesciencesspac.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in CMII’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.